Evoke Pharma, Inc. (EVOK)
| Market Cap | 43.79M |
| Revenue (ttm) | 350,076 |
| Net Income (ttm) | -9.29M |
| Shares Out | 32.39M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 148,143 |
| Open | 1.27 |
| Previous Close | 1.27 |
| Day's Range | 1.24 - 1.35 |
| 52-Week Range | 0.96 - 5.00 |
| Beta | 1.18 |
| Analysts | Buy |
| Price Target | 9.00 (+597.7%) |
| Est. Earnings Date | Nov 9, 2021 |
About EVOK
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was inc...
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for Evoke Pharma stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 597.67% from the latest price.
News
Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced t...
Chewy CEO Sumit Singh said online pet retailer wants to evoke same feelings as Disney World
The online pet retailer developed a cult following for its fast shipping and automatic deliveries of food and supplies.
What's Up With Evoke Pharma's Stock Popping Off Friday?
Evoke Pharma Inc (NASDAQ: EVOK) shares are trading higher by 23.1% at $1.38 after the company reported better-than-expected second-quarter EPS results. Evoke Pharma reported quarterly losses of 7 cents ...
Evoke Pharma Reports Second Quarter 2021 Financial Results
Approximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti ®
Evoke Pharma and EVERSANA Announce Support of The International Foundation for Gastrointestinal Disorders' (IFFGD) Au...
Participating and Sponsorship in Upcoming Digestive Health Virtual Walk Participating and Sponsorship in Upcoming Digestive Health Virtual Walk
Evoke Pharma Launches Gimoti® Patient and Physician Experience Program
Program intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providers Program intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providers
Evoke Pharma, EVERSANA and The International Foundation for Gastrointestinal Disorders Announce Membership into IFFGD...
Extends commitment toward supporting patients experiencing Diabetic Gastroparesis through focused collaborations and Sponsorship of the 30th Anniversary Digestive Health Virtual Walk Extends commitment ...
Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research Study
Results demonstrate continued increased awareness and intent to prescribe GIMOTI Results demonstrate continued increased awareness and intent to prescribe GIMOTI
Evoke Pharma Announces FDA Orange Book Listing of U.S. Patent for Gimoti®
SOLANA BEACH, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced th...
Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal Spray
Evoke is committed to meeting patients online, where they search for answers
Evoke Pharma Appoints Vickie Reed to Board of Directors
SOLANA BEACH, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the...
Evoke Pharma Reports First Quarter 2021 Financial Results
Nearly 293% growth of product sales, 235% growth of prescriptions and 87% increase in new prescribers for Gimoti ®
Evoke Pharma to Report First Quarter 2021 Financial Results on May 12, 2021
SOLANA BEACH, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today...
Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent w...
New patent expands intellectual property protection for nasal delivery of metoclopramide New patent expands intellectual property protection for nasal delivery of metoclopramide
Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis
SOLANA BEACH, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a commercial stage specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders ...
Why ContraFect, Evoke, Altimmune, Novavax Are Moving Friday
Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX), Evoke Pharma, Inc. (NASDAQ: EVOK), Altimmune, Inc. (NASDAQ: ALT) and Novavax, Inc. (NASDAQ: NVAX). Here's why the sto...
Evoke Pharma, Inc. (EVOK) Reports Q4 Loss, Misses Revenue Estimates
Evoke Pharma, Inc. (EVOK) delivered earnings and revenue surprises of -125.00% and -98.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Evoke Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
SOLANA BEACH, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, tod...
Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purcha...
SOLANA BEACH, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, anno...
Evoke Pharma Announces Pricing of Public Offering of Common Stock
SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, toda...
Evoke Pharma Announces Proposed Public Offering of Common Stock
SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, toda...
Evoke Pharma Announces Positive Findings from GIMOTI™ Market Research Study
Healthcare practitioner survey indicates physicians' awareness and intent to prescribe newly-launched product Healthcare practitioner survey indicates physicians' awareness and intent to prescribe newly...
Do Options Traders Know Something About Evoke Pharma (EVOK) Stock We Don't?
Investors need to pay close attention to Evoke Pharma (EVOK) stock based on the movements in the options market lately.
Evoke Pharma Reports Third Quarter 2020 Financial Results
Gimoti™ commercial launch underway
Evoke and EVERSANA Announce Commercial Launch of Gimoti™
Product launch provides healthcare providers a novel treatment approach for patients suffering from symptoms of acute and recurrent diabetic gastroparesis Product launch provides healthcare providers a ...